Celebrating Two Years of Ownership by Limerston Capital

This week (31 March 2025) marks two years since Concept Life Sciences came under Limerston Capital ownership. The company has undergone significant growth and transformation as a result of close collaboration with its customers, dedication from its employees, and continuous investments from Limerston Capital.

‍

Key achievements

• Helped customers advance 9 new drugs towards the clinic in 2024 alone:
  • 7 to clinical trial and 2 to preclinical stage
  • One customer’s drug was successfully launched to the market in the last 3 months
• This makes Concept Life Sciences's additive track record of helping customer accelerate 5 drugs to the market, 28 to the clinic, and 44 to preclinical stage
  ‍
• Successfully executed on post-merger integration of Charnwood Discovery, which brought a talented team of scientists and world-class biotech clients into the  Concept Life Sciences family
  ‍
• Invested in equipment and top-tier talent in areas such as protein production, cell painting and ADME automation
  ‍
• Launched capabilities in new modalities such as Peptide Discovery and Cell & Gene Therapy
  ‍
• Enhanced the Scientific Advisory Board with KOLs such as Professor Luke O’Neill and Dr Shane Liddelow
  ‍
• Received nominations from industry award bodies such as BioNOW and SCI-RSC Retrosynthesis demonstrating the quality of our team and services

‍

We look forward to the next phase of Concept Life Sciences' incredible growth journey and delivering high quality science to our customer.